当前位置:循环首页>正文

[ESC2010]房颤治疗策略——GYH Lip教授专访

作者:国际循环网   日期:2010/9/7 11:52:00

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

《国际循环》:最近有哪些抗凝药物您比较感兴趣?这些药物是否有潜力替代华法林用于房颤的抗凝治疗?


    <International Circulation>: Could you please discuss the latest anticoagulation agents? Do they have the potential to replace warfarin in anticoagulation therapy for AF?
    Prof. Lip:That is a very important question because these are very exciting times. We have had anticoagulation therapy with the vitamin K antagonists such as warfarin for a very long time but it is inconvenient, needs monitoring, and there is a degree of what is called “disutility” with warfarin due to its limitations. We now have new anticoagulants that belong to the two broad classes – the direct thrombin inhibitors and oral factor Xa inhibitors.

    For the direct thrombin inhibitors we have stunning data from the RE-LY trial with the oral direct thrombin inhibitor dabigatran. This certainly shows that it is effective therapy, very safe, and less intracranial hemorrhage compared to warfarin. In this meeting of the ESC, we have also seen excellent data from the AVERROES trial with the oral factor Xa inhibitor apixaban in the context of treatment of patients who have either failed warfarin therapy or declined warfarin therapy. Current practice under the older guidelines is that if patients can not take warfarin they are prescribed aspirin. I think that the AVERROES trial has clearly shown that this is inferior therapy and treatment with an anticoagulant such as apixaban is probably better tolerated or as safe as giving these patients aspirin. Thus, the new ESC Guidelines published at this meeting stress that oral anticoagulation therapy is the best treatment for stroke prevention in AF. Furthermore, we should be moving away the artificial categorization to low-risk, moderate-risk, and high-risk strata and there should be much more emphasis on a risk factor-based approach to providing thromboprophylaxis for stroke prevention in AF.

  《国际循环》:最近有哪些抗凝药物您比较感兴趣?这些药物是否有潜力替代华法林用于房颤的抗凝治疗?
    Lip教授:这是一个非常重要的问题,我们所处的时代不断有新惊喜出现。维生素K拮抗剂华法林作为抗凝药物已经应用了很长时间,但是华法林用药不方便,需要监测。由于华法林的上述局限性,使得存在某种程度上的华法林“无效”。目前有两类新型抗凝药物:直接凝血酶抑制剂和口服因子Xa抑制剂。在直接凝血酶抑制剂方面,有来自RE-LY试验的达比加群的非常好的数据,显示达比加群的确是非常有效的治疗,同时具有良好的安全性,颅内出血的发生率显著低于华法林。在本届ESC年会上,我们看到口服因子Xa抑制剂阿哌沙班来自AVERROES试验的很好的研究结果,用于华法林治疗无效或未接受华法林治疗者。在目前的临床实践中,如果患者不能应用华法林的话,依据旧版指南就给患者应用阿司匹林。我认为,AVERROES试验清楚地证实阿司匹林并不是优选治疗。阿哌沙班等抗凝药物耐受性更好或者安全性与阿司匹林相仿。在本届ESC年会上公布的新指南强调抗凝治疗是预防房颤患者卒中发生的最佳手段。我们应当从低、中和高危的人为危险分层转向依据危险因素给予抗栓药物以预防房颤患者的卒中发生。

[1]  [2]  下一页

版面编辑:沈会会  责任编辑:张衡


房颤治疗GYH Lip

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530